RxDoctor Payments Data

Brian Kuronya, DO

Family Medicine · Bethlehem, PANPI 1831202654

Payments from drug & device makers

$26,635in general payments, 2019–2025

Across 1,522 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$3K
  • Novo Nordisk$2K
  • Amgen$2K
  • Boehringer Ingelheim$2K
  • Pfizer$2K
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$25,75297%
  • Education$8833%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)215$3,136
AstraZeneca126$3,124
Novo Nordisk159$2,461
Amgen(2 entities)136$1,973
Boehringer Ingelheim82$1,783
Pfizer119$1,741
Lilly USA, LLC102$1,502
Astellas Pharma US Inc50$1,370
Merck51$815
Otsuka America Pharmaceutical, Inc.38$800
Lundbeck LLC41$629
Bayer29$609
Exact Sciences19$443
Paratek Pharmaceuticals, Inc.19$371
GSK25$358
Kowa Pharmaceuticals America, Inc.23$354
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC24$346
Axsome Therapeutics, Inc.13$338
Optinose US, Inc.10$301
Mannkind Corporation18$278
Johnson & Johnson(2 entities)15$271
Abbott12$254
Amarin Pharma, Inc.14$240
Bausch Health US, LLC11$229
Sumitomo Pharma America, Inc.12$226
Takeda Pharmaceuticals U.S.A., Inc.17$221
Antares Pharma, Inc.11$189
Biohaven Pharmaceuticals, Inc.10$151
Esperion Therapeutics, Inc.8$151
Biohaven Pharmaceutical Holding Company Ltd.8$140
Novartis8$135
E.r. Squibb & Sons, L.L.C.8$125
Sanofi-aventis U.S. LLC8$122
Sanofi Pasteur Inc.4$88
Medtronic4$85
Teva Pharmaceuticals USA, Inc.5$84
Almatica Pharma LLC4$74
Madrigal Pharmaceuticals3$69
Eisai Inc.3$63
Arbor Pharmaceuticals, Inc.4$58
Sunovion Pharmaceuticals Inc.4$57
Pacira Therapeutics, Inc.4$56
Philips North America LLC3$53
Phathom Pharmaceuticals, Inc.3$52
Scilex Pharmaceuticals Inc.3$45
Tolmar, Inc.3$44
Alnylam Pharmaceuticals Inc.2$42
Radius Health, Inc.2$40
Phadia US Inc.2$37
Verity Pharmaceuticals Inc.2$35
Vanda Pharmaceuticals Inc.2$34
Shire North American Group Inc2$30
Neurelis, Inc.2$29
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$24
UCB, Inc.1$24
Supernus Pharmaceuticals, Inc.1$22
Hikma Pharmaceuticals USA1$22
Corcept Therapeutics1$22
Gilead1$22
Cumberland Pharmaceuticals, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,635 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$222,114
Medicare patients
470
Services billed
6,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$171,136
JardianceEmpagliflozin171$141,405
MounjaroTirzepatide57$76,030
RybelsusSemaglutide41$74,934
OzempicSemaglutide49$57,743
AtivanLorazepam13$44,221
XareltoRivaroxaban40$38,159
TrulicityDulaglutide21$37,845
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$27,418
SynjardyEmpagliflozin/Metformin Hcl29$26,899
Synjardy XrEmpagliflozin/Metformin Hcl16$23,460
JanuviaSitagliptin Phosphate32$23,075
RexultiBrexpiprazole16$22,912
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$22,330
FarxigaDapagliflozin Propanediol31$22,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Spiriva Respimat, Stiolto Respimat$1,783$213,536261 claims
PfizerEliquis$1,741$171,136206 claims
Novo NordiskRybelsus, Ozempic$2,461$132,67790 claims
Lilly USA, LLCMounjaro, Trulicity$1,502$113,87678 claims
AstraZenecaBreztri Aerosphere, Farxiga$3,124$49,51772 claims
Johnson & JohnsonXarelto, Invokana$271$49,41654 claims
GSKAnoro Ellipta, Breo Ellipta$358$31,74451 claims
MerckJanuvia$815$23,07532 claims
Otsuka America Pharmaceutical, Inc.Rexulti$800$22,91216 claims
Astellas Pharma US IncMyrbetriq$1,370$20,38735 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$221$14,32331 claims
AbbVieSynthroid$3,136$6,288130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →